Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment

Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment

Background: The current use of ribavirin in difficult-to-cure chronic hepatitis C patients (HCV) and patients with severe respiratory infections is constrained by the issue of ribavirin-induced hemolytic anemia that affects 30% of treated patients, requiring dosage modification or discontinuation. T...

Full description

Bibliographic Details
Main Authors: Jennifer J. Lin, Catrina M. Loucks, Jessica N. Trueman, Britt I. Drögemöller, Galen E.B. Wright, Eric M. Yoshida, Jo-Ann Ford, Samuel S. Lee, Richard B. Kim, Bandar Al-Judaibi, Ute I. Schwarz, Alnoor Ramji, Edward Tam, Colin J. Ross, Bruce C. Carleton
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Ribavirin
Pharmacogenomics
Adverse reactions
HCV
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332221009793

Internet

http://www.sciencedirect.com/science/article/pii/S0753332221009793

Similar Items